The
global fluvoxamine market size was valued at USD 592 million in 2020 and projected to grow at a significant CAGR of 3% during the forecast period 2021 to 2027. The rising prevalence of anxiety and depression across the globe is a major factor to drive the market growth. Moreover, the increasing incidence of social anxiety disorder is expected to propel the market growth over the forecast period.
The global fluvoxamine market is bifurcated into clinical application, distribution channel, and geography. On the basis of clinical application, the market is further segmented into obsessive-compulsive disorder, post-traumatic disorder, and others. According to the latest stats shared by NIH, around 2.3% of populations experience obsessive-compulsive disorder around the globe.